Adaptive Biotechnologies (NASDAQ: ADPT) CEO Chad Robins sells 124,998 shares

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported selling 124,998 shares of the company’s common stock on January 5, 2026 at a weighted average price of $15.59 per share. After this sale, he beneficially owned 2,584,243 shares directly.

The transaction was coded as an open market or private sale and was carried out under a Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. The filing notes that the shares were sold in multiple trades at prices ranging from $15.31 to $15.96, and that detailed trade-by-trade information is available upon request.

Insider Trade Summary

Net Seller: 124,998 shares ($1,948,719)

Net Sell 1 txn

Insider ROBINS CHAD M

Role CEO and Chairman

Sold 124,998 shs ($1.95M)

Type	Security	Shares	Price	Value
Sale	Common Stock	124,998	$15.59	$1.95M

Holdings After Transaction: Common Stock — 2,584,243 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.31 to $15.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS CHAD M

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		124,998	D	$15.59(2)	2,584,243	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.31 to $15.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who sold shares of Adaptive Biotechnologies Corp (ADPT) in this Form 4?

Chad M. Robins, the CEO, Chairman, and a director of Adaptive Biotechnologies Corp, is the reporting person for this Form 4 transaction.

How many ADPT shares did Chad M. Robins sell and at what price?

He sold 124,998 shares of Adaptive Biotechnologies common stock at a weighted average price of $15.59 per share, with individual trades ranging from $15.31 to $15.96.

How many Adaptive Biotechnologies (ADPT) shares does Chad M. Robins own after this transaction?

Following the reported sale, Chad M. Robins beneficially owned 2,584,243 shares of Adaptive Biotechnologies common stock in direct ownership.

Was the ADPT share sale by Chad M. Robins under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Chad M. Robins on August 11, 2025.

What type of transaction is reported in this Adaptive Biotechnologies (ADPT) Form 4?

The Form 4 reports an open market or private sale of common stock, coded as transaction type S in the non-derivative securities table.

Does the Form 4 provide detailed pricing for each ADPT trade executed?

The filing states that the reported price is a weighted average and that the shares were sold between $15.31 and $15.96. It also notes that full trade details are available upon request.